IXICO Revenue and Competitors

London, UK

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • IXICO's estimated annual revenue is currently $15.8M per year.(i)
  • IXICO's estimated revenue per employee is $155,000

Employee Data

  • IXICO has 102 Employees.(i)
  • IXICO grew their employee count by -7% last year.

IXICO's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
CFOReveal Email/Phone
3
Head Human ResourcesReveal Email/Phone
4
VP Operations ServicesReveal Email/Phone
5
Head IT Quality and Software ValidationReveal Email/Phone
6
VP Business DevelopmentReveal Email/Phone
7
VP TechnologyReveal Email/Phone
8
SVP Quality, Compliance & Regulatory AffairsReveal Email/Phone
9
VP Strategic Project DeliveryReveal Email/Phone
10
Associate Director, Clinical ScienceReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.5M29-12%N/AN/A
#2
$15.7M1015%N/AN/A
#3
$87.9M40525%$292MN/A
#4
$2.6M47016%$631.7MN/A
#5
$14.9M96-8%$81MN/A
#6
$44.8M2310%$132.9MN/A
#7
$7.6M49-37%N/AN/A
#8
$17.4M11212%N/AN/A
#9
$334.6M134911%£994.6MN/A
#10
$830.2M53568%N/AN/A
Add Company

What Is IXICO?

IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the advancement of investigational therapies for neurological diseases through the application of medical image analysis and digital health technologies, bringing safe and effective treatment to patients sooner. \n\nIXICO’s digital platform and Artificial Intelligence (AI) software are used by the global pharmaceutical industry to collate and interpret brain scan data from MRI and positron emission tomography (PET) scanners, as well as making sense of real world data collected using wearable biosensors. Our specialist data analytics services extract biomarkers from brain scan and wearable biosensor data to enable better patient selection, quantification of disease progression and assessment of patient outcomes. \n\nWe provide technology-enabled services across all clinical trial phases as well as in post marketing surveillance, and our integrated digital platform provides a scalable and secure infrastructure to manage the standardisation, capture and analysis of regulatory compliant clinical data. Our neuroimaging and digital biomarkers are powering some of the most important clinical trials in neuroscience today, enabling our clients to design better trials and make rapid, better informed assessments of drugs safety and efficacy. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.

keywords:N/A

N/A

Total Funding

102

Number of Employees

$15.8M

Revenue (est)

-7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

IXICO News

2022-04-19 - IXICO lands £800,000 Huntington"s contract

IXICO lands £800,000 Huntington's contract. It will support a global observational study to assess participants for the early detection of the...

2022-04-17 - Bouncing back: IXICO

Medical imaging technology provider IXICO (LON: IXI) found this out when phase III clinical trial for a Huntington's disease drug was...

2022-04-13 - Is It Time To Consider Buying IXICO plc (LON:IXI)?

IXICO plc (LON:IXI), might not be a large cap stock, but it received a lot of attention from a substantial price movement on the AIM over...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$14.8M102-3%$39M
#2
$24.8M10236%N/A
#3
$14.8M10262%$1M
#4
$14.8M102-1%N/A
#5
$15M10210%N/A